MARTIN TH	EODORE E											
Form 4	2000											
November 25,												
FORM	4 UNITED S	STATES					E CO	MMISSION	OMB AF OMB Number:	PROVAL 3235-0287		
Check this	box											
if no longe subject to Section 16 Form 4 or	SIAIEM	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Expires:January 31Expires:2005Estimated averageburden hours perresponse0.5			
Form 5 obligations may contir <i>See</i> Instruc 1(b).	Section 17(a	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Re	esponses)											
1. Name and Address of Reporting Person <u>*</u> MARTIN THEODORE E			Symbol					5. Relationship of Reporting Person(s) to Issuer				
	APPLIED BIOSYSTEMS INC. [ABI]					(Check all applicable)						
(Month/Da				ay/Year)			X_ Director10% Owner Officer (give titleOther (specify below) below)					
APPLIED BI MERRITT 7	OSYSTEMS IN	C., 301	11/21/20	08				,	,			
	(Street)				onth/Day/Year) A				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NORWALK,	CT 06851-1070)					_	Form filed by Me erson				
(City)	(State)	(Zip)	Table	I - Non-De	rivative Sec	urities	Acqui	red, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deeme Execution I any (Month/Day/Year)			n Date, if Transaction(A) or Disposed of (E Code (Instr. 3, 4 and 5) Day/Year) (Instr. 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Applied				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)			
Biosystems Group Common Stock Units	11/21/2008			D	30,345.4 (1)	D	<u>(2)</u>	0	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number Transaction Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Ame or Nun of Shai
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 21.3619 (<u>3)</u>	11/21/2008		D	6,000 (<u>3)</u>	<u>(4)</u>	03/22/2009	Applied Biosystems Group Common Stock	6,0
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 35.7344 (<u>3)</u>	11/21/2008		D	6,000 (<u>3)</u>	<u>(4)</u>	10/21/2009	Applied Biosystems Group Common Stock	6,(
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 108.3125 (3)	11/21/2008		D	6,000 (<u>3)</u>	<u>(4)</u>	10/19/2010	Applied Biosystems Group Common Stock	6,0
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 27.975 (<u>3</u>)	11/21/2008		D	8,000 (<u>3)</u>	<u>(4)</u>	10/18/2011	Applied Biosystems Group Common Stock	8,0
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 20 <u>(3)</u>	11/21/2008		D	8,000 (<u>3)</u>	<u>(4)</u>	10/17/2012	Applied Biosystems Group Common Stock	8,0
Applied Biosystems Group	\$ 23.215 (3)	11/21/2008		D	7,500 (3)	<u>(4)</u>	10/16/2013	Applied Biosystems Group	7, <u>5</u>

Director Stock Options-Right to Buy							Common Stock	
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 18.905 (<u>3</u>)	11/21/2008	D	9,200 (<u>3)</u>	<u>(4)</u>	10/21/2014	Applied Biosystems Group Common Stock	9,2 (
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 35.985 (<u>3)</u>	11/21/2008	D	9,000 (<u>3</u>)	<u>(4)</u>	10/18/2017	Applied Biosystems Group Common Stock	9,(
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 23.25 (<u>3</u>)	11/21/2008	D	9,000 <u>(3)</u>	<u>(4)</u>	10/21/2015	Applied Biosystems Group Common Stock	9,(_(
Applied Biosystems Group Director Stock Options-Right to Buy	\$ 33.74 (3)	11/21/2008	D	9,000 (<u>3)</u>	<u>(4)</u>	10/20/2016	Applied Biosystems Group Common Stock	9,(<u>(</u>

Reporting Owners

Reporting Owner Name / Address			-		
	Director	10% Owner	Officer	Other	
MARTIN THEODORE E APPLIED BIOSYSTEMS INC. 301 MERRITT 7 NORWALK, CT 06851-1070	Х				
Signatures					
/s/ Thomas P. Livingston, Attorn Martin		11/25/2008			
**Signature of Repo		Date			

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Relationships

(1)

Includes 37.91 Applied Biosystems Group Common Stock Units acquired in October 2008 pursuant to the dividend reinvestment feature of the Company's director stock purchase and stock incentive plans.

On November 21, 2008, the issuer was acquired by Invitrogen Corporation (renamed Life Technologies Corporation) pursuant to an Agreement and Plan of Merger dated as of June 11, 2008 (as amended, the "merger agreement"). All deferred units for shares of the

(2) issuer's Applied Biosystems Group common stock ("ABI stock") held by the reporting person at the time of the merger were converted into a right to receive merger consideration pursuant to the merger agreement. The merger consideration for the converted deferred units consists of 0.8261 shares of Life Technologies common stock (plus an additional cash payment of \$1.91 per share paid as a merger consideration adjustment due to the trading price of ABI stock during a period of time specified prior to the merger).

Pursuant to the merger agreement, upon completion of the merger each outstanding award of options to purchase shares of ABI stock was converted into an award to purchase shares of Life Technologies Corporation common stock. Each new stock option award became an $\frac{1}{2}$

(3) award to purchase shares of Life Technologies common stock in an amount equal to the product of (x) 0.8698, multiplied by (y) the number of shares of ABI stock underlying the stock option award outstanding as of closing (rounded down to the nearest share). The exercise price per share of each converted option is equal to the exercise price per share of the option prior to conversion divided by the exchange ratio of 0.8698 (rounded up to the nearest cent).

All of these ABI stock options were fully vested and free from all restrictions upon the completion of the merger described in Note 2(4) above. Some of the options held by the reporting person and reported in Table II vested at various dates prior to the merger. Pursuant to the merger agreement, options that had not vested prior to the merger became fully vested upon completion of the merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.